vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective on the stock.

vTv Therapeutics Trading Down 2.7 %

VTVT opened at $19.65 on Friday. The company has a market cap of $62.67 million, a P/E ratio of -4.34 and a beta of 0.73. The business’s 50-day moving average price is $15.76 and its 200-day moving average price is $15.15. vTv Therapeutics has a 12 month low of $8.10 and a 12 month high of $30.99.

Institutional Trading of vTv Therapeutics

Several large investors have recently bought and sold shares of VTVT. FMR LLC bought a new stake in vTv Therapeutics during the 3rd quarter valued at approximately $2,402,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the 4th quarter valued at approximately $25,000. Finally, Geode Capital Management LLC boosted its position in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. 17.51% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.